A Phase 2 clinical trial evaluating thymosin alpha-1 changed status to completed on August 3, 2026. The study, registered as NCT06139419, examined the impact of thymosin alpha-1 on the efficacy of concurrent chemoradiotherapy followed by immunotherapy consolidation in patients with locally advanced non-small cell lung cancer.
Thymosin alpha-1 remains classified as an unapproved compound used only in research settings. The trial record lists its phase as Phase 2 and its current status as completed, according to the ClinicalTrials.gov listing.
No results, outcome data, or efficacy conclusions were included in this update. The completed status reflects only that the trial has concluded its conduct phase, not that findings have been published or reviewed. Readers should not interpret this update as evidence of benefit or harm associated with thymosin alpha-1 in this treatment context.
Further details on trial design, enrollment, and any eventual results would be found in subsequent postings to the same registry entry. For background on this compound, see the linked compound overview.